Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Capital Expenditures (2016 - 2025)

Surgery Partners' Capital Expenditures history spans 12 years, with the latest figure at $12.8 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 42.6% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $78.7 million, down 12.94%, while the annual FY2025 figure was $78.7 million, 12.94% down from the prior year.
  • Capital Expenditures for Q4 2025 was $12.8 million at Surgery Partners, down from $19.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $26.9 million in Q2 2024 and bottomed at $12.8 million in Q4 2025.
  • The 5-year median for Capital Expenditures is $20.0 million (2023), against an average of $19.8 million.
  • The largest annual shift saw Capital Expenditures skyrocketed 96.2% in 2021 before it plummeted 42.6% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $14.1 million in 2021, then soared by 60.99% to $22.7 million in 2022, then dropped by 12.78% to $19.8 million in 2023, then increased by 12.63% to $22.3 million in 2024, then tumbled by 42.6% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Capital Expenditures are $12.8 million (Q4 2025), $19.8 million (Q3 2025), and $23.4 million (Q2 2025).